Summary by Moomoo AI
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its upcoming 2024 Annual Meeting of Stockholders. The meeting is scheduled to be held virtually on June 13, 2024, at 1:00 p.m. Pacific Time. The proxy statement outlines several key proposals, including the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the authorized number of shares of common stock from 40,000,000 to 80,000,000. The company, which was incorporated as Locust Walk Acquisition Corp. and underwent a business combination to become eFFECTOR Therapeutics, Inc., is inviting stockholders to attend the meeting online and cast their votes on these matters. The proxy materials are available on the Internet as part of the company's efforts to reduce environmental impact and delivery costs.